

| Research Ethics Committee Reference Number | Integrated Research Application System (IRAS) number | Name of Trial  | Target number of patients agreed? | Min. number of patients agreed | Max. number of patients agreed | Target date to recruit patients agreed? | Date agreed to recruit target number of patients | Total number of patients recruited at the agreed target date | Total number of study participants recruited | Date that the trial closed to recruitment | Reason for closure of trial | Comments   |
|--|--|--|-----------------------------------|--------------------------------|--------------------------------|---|--|--|--|---|-----------------------------|--|
| 15/WS/0061                                 | 178522   | A Randomized, Doubleblind, Eventdriven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease | Number Agreed                     | 5                              | 5                              | Date Agreed                             | 30/09/2016                                       | 1  | 1  | 27/07/2017                                | Recruitment Finished        | Exceptionally strict eligibility criteria. Approximately 10 eligible patients seen at site but only one consented to participate.                    |
| 17/EM/0089                                 | 222705   | BREAKOUT - International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study   | Number Agreed                     | 7                              | 7                              | Date Agreed                             | 31/12/2017                                       | 3  | 3  | 15/09/2017                                | Withdrawn By Sponsor        | Unfortunately the study was stopped prematurely by the sponsor. We were on track to meet our recruitment target by the planned recruitment end date. |
| 14/SC/1161                                 | 155743   | Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.  | Number Agreed                     | 30                             | 30                             | Not Available / Not Agreed              |  |  | 21   | 17/04/2018                                | Recruitment Finished        | Global competition.  |
| 16/EM/0133                                 | 184873   | A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerability and efficacy up to 2 years in patients with active nonradiographic axial spondyloarthritis  | Number Agreed                     | 5                              | 5                              | Date Agreed                             | 25/07/2017                                       | 0  | 1  | 30/03/2018                                | Recruitment Finished        | Three additional patients screen failed prior to randomisation. Lack of patients meeting inclusion criteria.   |
| 17/EM/0075                                 | 222172   | Evaluating the tolerance, compliance and acceptability of a nutritionally complete, high energy, high protein, enteral feed in adults - a pilot study  | Range Agreed                      | 5                              | 10                             | Date Agreed                             | 01/09/2017                                       | 7  | 9  | 31/05/2018                                | Recruitment Finished        |  |